Perfect the Biochemistry Behind ADC Synthesis, Vaccine and Nanoparticle Conjugation


Online Registration is Open!
Register by Friday, March 18 to Save Up to $400!
»Pricing Chart

Add to Outlook Calendar

Find Another IBC Event

Transitioning Innovation into Viable Therapeutic Candidates

June 13-15, 2016
Parc 55 Hilton
San Francisco, CA

Alt language

Alternative Language Options:

  • Japanese
  • Korean
  • Taiwanese
  • Chinese

Event Overview

Event Overview


Where the drug discovery community gathers to:

  • Develop Platforms to Support Novel Linkers and Payloads
    • Explore how the new class of DNA-alkylating agents are designed and synthesized
    • Mitigate toxicity risks and ensure proper potency with the latest data from Genentech and Immunogen
  • Help define CMC standards
    • Combat analytical and characterization challenges with new data from MedImmune
    • Learn how Pfizer creates characterization roadmaps to evaluate molecular complexity and critical quality attributes
  • Understand conjugate advances beyond ADCs
    • Hear the latest data on bispecific, nano-particle, and vaccine conjugation
    • Eliminate heterogeneity and increase the therapeutic window with new data from GSK and Pfizer

View the Agenda

Turn your research into viable therapeutic candidates with

  • Annaliesa S. Anderson, Ph.D. photo Annaliesa Anderson, Ph.D. VP & CSO Bacterial Vaccines, VRD, Pfizer, Inc.
  • Dimiter Dimitrov, Ph.D. photo Dimiter Dimitrov, Ph.D. Senior Investigator, Protein Interactions, National Cancer Institute, NIH
  • Greg Adams, Ph.D. photo Greg Adams, Ph.D. Chief Development Officer, Viventia Biotechnologies Inc
  • Thomas Pillow, Ph.D. photo Thomas Pillow, Ph.D. Scientist, ADC Team Leader, Genentech

Join the industry's leading Conjugation Conference

  • 100+ Attendees
  • 20+ New Data sessions
  • 10+ Hours of Dedicated Networking

Networking Opportunities

Sponsors and Exhibitors

Position yourself as a thought leader and showcase your innovations to an engaged community of scientists and researchers. Contact Patricia Rose at to receive the sponsor prospectus and to discuss custom packages.

Showcase at the Event

Unite discovery, research and development

  • Access 80+ New Data And Case Study Presentations
    Bioconjugates: From Targets to Therapeutics is co-located with Next Generation Protein Therapeutics and Cell Line Development & Engineering resulting in a unique collaborative experience where experts share insights and inspiring data.
  • All-Access Pass Upgrade
    When you upgrade to the all-access pass you gain the opportunity to collaborate with the entire drug discovery and development ecosystem. Connect with process development and other protein engineers to ensure therapeutic success.
  • A Team Experience
    With so much content and 400+ attendees to meet with packed, you'd need to bring your team to cover it all. Group discounts are available.

Co-Located Events